Involvement of K-RAS mutations and amino acid substitutions in the survival of metastatic colorectal cancer patients.

Abstract

e14116 Background: The efficacy against of epidermal growth factor therapy was found to be limited to those wild-type K-RAS tumours, suggesting a predictive value of response. However, the prognostic value of K-RAS status is controversial. The aim is to determine the relationship between K-RAS mutations and types of amino acid changes with the survival (OS) of metastatic colorectal patients (mCRC). Methods: The retrospective analysis included 120 patients diagnosed of mCRC. The presence and type of K-RAS mutations were analysed. Similarly, the clinical and pathological variables were also collected including OS. Results: The sample characteristics were summarized in Table 1. 53.3% of tumours were wild-type and 46.7 mutated KRAS. In mutated patients, codon 12 was affected in 76.79% and codon 13 in 23.21%. The median OS for wild-type was 31.6 months. In mutated patients (codon 12 or 13), median OS was 24.8 and 17.8 months (p=0.37), respectively. In the univariate analysis, mutated K-RAS was associated with stage IV at diagnosis (p<0.005). The relationship between OS and amino acid mutation are summarized in table 1. Conclusions: Our study suggest that the types of mutation or amino acid changes of KRAS in mCRC provides prognostic information. These data need to be confirmed in prospective or controlled trials. [Table: see text]